Long-chain n-3 polyunsaturated fatty acids

new insights into mechanisms relating to inflammation and coronary heart disease

Baukje De Roos, Yiannis Mavrommatis, Ingeborg A Brouwer

    Research output: Contribution to journalArticle

    93 Citations (Scopus)

    Abstract

    Evidence from observational studies, prospective cohort studies and randomized clinical intervention studies indicate that moderate doses of long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFA) significantly decrease risk of fatal coronary heart disease (CHD). Higher doses and longer duration of intervention may also protect from non-fatal CHD events. The exact mechanisms through which LC n-3 PUFA has an effect on CHD are not well established but may include a decrease in fasting and postprandial triacylglycerol levels, a decrease in arrhythmias, modulation of platelet aggregation and decreased synthesis of pro-inflammatory agents. The mechanistic relation between LC n-3 PUFA and inflammation has attracted great interest, and in vitro studies have revealed that these fatty acids decrease endothelial activation, affect eicosanoid metabolism (including epoxygenation pathways) and induce inflammatory resolution. However, the effects of LC n-3 PUFA on established biomarkers of inflammation and endothelial activation in vivo are not strong. Consequently we need new and more sensitive and systemic biomarkers to reveal the effects of LC n-3 PUFA on localized inflammatory processes.
    Original languageEnglish
    Pages (from-to)413-428
    Number of pages16
    JournalBritish Journal of Pharmacology
    Volume158
    Issue number2
    Early online date5 May 2009
    DOIs
    Publication statusPublished - Sep 2009

    Fingerprint

    Omega-3 Fatty Acids
    Coronary Disease
    Inflammation
    Biomarkers
    Eicosanoids
    Platelet Aggregation
    Observational Studies
    Cardiac Arrhythmias
    Fasting
    Triglycerides
    Cohort Studies
    Fatty Acids
    Prospective Studies

    Keywords

    • animals
    • biological markers
    • clinical trials as topic
    • coronary disease
    • dose-response relationship, drug
    • fatty acids, omega-3
    • humans
    • inflammation
    • fish oil
    • LC n-3 PUFA
    • mechanisms
    • coronary heart disease

    Cite this

    Long-chain n-3 polyunsaturated fatty acids : new insights into mechanisms relating to inflammation and coronary heart disease. / De Roos, Baukje; Mavrommatis, Yiannis; Brouwer, Ingeborg A.

    In: British Journal of Pharmacology, Vol. 158, No. 2, 09.2009, p. 413-428.

    Research output: Contribution to journalArticle

    @article{f9b5103116954503b9cdeff106037c8d,
    title = "Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease",
    abstract = "Evidence from observational studies, prospective cohort studies and randomized clinical intervention studies indicate that moderate doses of long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFA) significantly decrease risk of fatal coronary heart disease (CHD). Higher doses and longer duration of intervention may also protect from non-fatal CHD events. The exact mechanisms through which LC n-3 PUFA has an effect on CHD are not well established but may include a decrease in fasting and postprandial triacylglycerol levels, a decrease in arrhythmias, modulation of platelet aggregation and decreased synthesis of pro-inflammatory agents. The mechanistic relation between LC n-3 PUFA and inflammation has attracted great interest, and in vitro studies have revealed that these fatty acids decrease endothelial activation, affect eicosanoid metabolism (including epoxygenation pathways) and induce inflammatory resolution. However, the effects of LC n-3 PUFA on established biomarkers of inflammation and endothelial activation in vivo are not strong. Consequently we need new and more sensitive and systemic biomarkers to reveal the effects of LC n-3 PUFA on localized inflammatory processes.",
    keywords = "animals, biological markers, clinical trials as topic, coronary disease, dose-response relationship, drug, fatty acids, omega-3, humans, inflammation, fish oil, LC n-3 PUFA, mechanisms, coronary heart disease",
    author = "{De Roos}, Baukje and Yiannis Mavrommatis and Brouwer, {Ingeborg A}",
    year = "2009",
    month = "9",
    doi = "10.1111/j.1476-5381.2009.00189.x",
    language = "English",
    volume = "158",
    pages = "413--428",
    journal = "British Journal of Pharmacology",
    issn = "0007-1188",
    publisher = "Wiley-Blackwell",
    number = "2",

    }

    TY - JOUR

    T1 - Long-chain n-3 polyunsaturated fatty acids

    T2 - new insights into mechanisms relating to inflammation and coronary heart disease

    AU - De Roos, Baukje

    AU - Mavrommatis, Yiannis

    AU - Brouwer, Ingeborg A

    PY - 2009/9

    Y1 - 2009/9

    N2 - Evidence from observational studies, prospective cohort studies and randomized clinical intervention studies indicate that moderate doses of long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFA) significantly decrease risk of fatal coronary heart disease (CHD). Higher doses and longer duration of intervention may also protect from non-fatal CHD events. The exact mechanisms through which LC n-3 PUFA has an effect on CHD are not well established but may include a decrease in fasting and postprandial triacylglycerol levels, a decrease in arrhythmias, modulation of platelet aggregation and decreased synthesis of pro-inflammatory agents. The mechanistic relation between LC n-3 PUFA and inflammation has attracted great interest, and in vitro studies have revealed that these fatty acids decrease endothelial activation, affect eicosanoid metabolism (including epoxygenation pathways) and induce inflammatory resolution. However, the effects of LC n-3 PUFA on established biomarkers of inflammation and endothelial activation in vivo are not strong. Consequently we need new and more sensitive and systemic biomarkers to reveal the effects of LC n-3 PUFA on localized inflammatory processes.

    AB - Evidence from observational studies, prospective cohort studies and randomized clinical intervention studies indicate that moderate doses of long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFA) significantly decrease risk of fatal coronary heart disease (CHD). Higher doses and longer duration of intervention may also protect from non-fatal CHD events. The exact mechanisms through which LC n-3 PUFA has an effect on CHD are not well established but may include a decrease in fasting and postprandial triacylglycerol levels, a decrease in arrhythmias, modulation of platelet aggregation and decreased synthesis of pro-inflammatory agents. The mechanistic relation between LC n-3 PUFA and inflammation has attracted great interest, and in vitro studies have revealed that these fatty acids decrease endothelial activation, affect eicosanoid metabolism (including epoxygenation pathways) and induce inflammatory resolution. However, the effects of LC n-3 PUFA on established biomarkers of inflammation and endothelial activation in vivo are not strong. Consequently we need new and more sensitive and systemic biomarkers to reveal the effects of LC n-3 PUFA on localized inflammatory processes.

    KW - animals

    KW - biological markers

    KW - clinical trials as topic

    KW - coronary disease

    KW - dose-response relationship, drug

    KW - fatty acids, omega-3

    KW - humans

    KW - inflammation

    KW - fish oil

    KW - LC n-3 PUFA

    KW - mechanisms

    KW - coronary heart disease

    U2 - 10.1111/j.1476-5381.2009.00189.x

    DO - 10.1111/j.1476-5381.2009.00189.x

    M3 - Article

    VL - 158

    SP - 413

    EP - 428

    JO - British Journal of Pharmacology

    JF - British Journal of Pharmacology

    SN - 0007-1188

    IS - 2

    ER -